qlsyy.net - QLI Total Company Value-to-Revenue Ratio

Official company branding of qlsyy.net (QLI)

Chinese generic drug and organic compound manufacturer Qilian International (QLI) is modernizing its raw material synthesis, while the enterprise value-to-revenue multiple reflects a trend where the indicator reaches . High barriers to entry are maintained through government licensing and component quality. The stability of the technical staff is further enhanced by the strategic hiring of external sales experts.

QLI qlsyy.net Enterprise Value-to-Revenue Ratio (07/04/2022 - 11/20/2026)

Qilian International Corp - analytical breakdowns and key metrics (QLI)

Initial company analysis:Qilian International Holding, QLI
Product sample of Qilian International Holding Group Limited

To objectively assess the operational efficiency of Qilian International (QLI), it is essential for investors to understand the real value of the business without the distortions introduced by debt load. By analyzing the enterprise value-to-sales multiple, you compare the total asset value with the revenue generated from the innovative extraction of bioactive substances, which helps determine whether the market price of the shares is fair relative to the issuer's technological potential within the chemical industry.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|CYTO (altamiratherapeutics.com) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple LIPO|OPTN - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio pieris.com PIRS|Business Value to Revenue PROC|PTPI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio